1. EWTX will present at the Goldman Sachs Healthcare Conference on June 9, 2025. 2. The presentation will be webcast live and available for replay. 3. EWTX develops novel therapeutics for muscle diseases and cardiac conditions. 4. Sevasemten is in late-stage trials for muscular dystrophies. 5. EDG-7500 is in Phase 2 for hypertrophic cardiomyopathy treatment.
Presentations at major conferences often boost investor interest and visibility for biotech companies, similar to past conferences that led to stock rises for companies showcasing promising therapeutics.
The announcement emphasizes EWTX's innovation and engagement with the investment community, likely affecting investor sentiment positively.
The immediate visibility from the conference can generate short-term investor enthusiasm and potential stock price appreciation.
BOULDER, Colo., June 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Annual Goldman Sachs Global Healthcare Conference on Monday, June 9, 2025 at 3:20 pm ET.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X, Facebook and Instagram.
SOURCE Edgewise Therapeutics